Surgical outcomes of cerebellar liponeurocytomas: A systematic review and individual patient data meta-analysis.

J Clin NeurosciMay 17, 2026 (epub)
Clinical ResearchNeurosurgeryOncology (Medical)

Thuc Nhi Lu, Boyuan Khoo, Barry Ting Sheen Kweh

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and individual patient data meta-analysis examined surgical outcomes of cerebellar liponeurocytomas in 84 cases. The study found a 5-year overall survival rate of 91.7% and a progression-free survival rate of 80.9%. Gross total resection significantly improved progression-free survival compared to subtotal resection.

Key findings

  • 5-year overall survival rate was 91.7% (95% CI 84.9%-99%).
  • Progression-free survival rate was 80.9% (95% CI 70.6%-92.7%).
  • Gross total resection improved progression-free survival compared to subtotal resection (p = 0.01).
  • Post-operative adjuvant radiotherapy after subtotal resection was associated with improved progression-free survival.

Why it matters

Understanding the surgical outcomes and prognostic factors of cerebellar liponeurocytomas can guide clinicians in treatment planning and patient counseling, particularly regarding the benefits of gross total resection and the role of adjuvant therapy.

Source

PubMed · PMID 42143885

Published in J Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.